List view / Grid view
The first US in-human trial of CRISPR-Cas9-edited T cells has concluded with no ill effects and showed that nine months later the infused cells were still active against cancer.
Dr Lazar’s team identified that TZDs, while working for PPAR gamma, promoted the metabolism of glutamine, an amino acid...
The onset of side effects of a common cancer treatment, anti-PD-1 therapy can be identified up to 3 years after treatment...
Penn study shows that cholesterol drug may help Friedreich's ataxia patients...
An antibody used to treat the skin disease psoriasis is also effective at reducing aortic inflammation, a key marker of future risk of major cardiovascular events...
A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer...
